BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 1
• 2
• 3
• 4
• 5
• 6
• 7
• 8
• 9
• 11
• 12
• 13
• 14
• 15
• 16
• 18
• 19
• 20
• 21
• 22
• 23
• 24
• 25
• 26
• 27
• 28
• 29

• Biotech Bay

  Sira Medical Wins FDA Clearance for Augmented Reality Preoperative Surgical Planning Software

  The U.S. Food and Drug Administration granted Sira Medical 510(k) clearance for its augmented reality preoperative surgical planning application, which provides clinicians with advanced imaging to assist in making key patient management decisions.

  February 21, 2024

   · 

  2 min read
• Sirona Biochem Announces Plans for Commercial Launch of GlycoProteMim™ in Early 2025

  Sirona Biochem Corp. (TSX-V: SBM) (FSE: ZSB) (US-OTC: SRBCF), also known as Sirona, is excited to share a new milestone in its journey.

  February 21, 2024

   · 

  2 min read
• Business

  William S. Marth Joins CONTINUUS Pharmaceuticals Board of Directors, Bringing Commercial Leadership and Manufacturing Expertise to the Company

  CONTINUUS Pharmaceuticals, a cutting-edge pharmaceutical firm specializing in end-to-end integrated continuous manufacturing, is pleased to announce the appointment of William S. Marth, RPh., MBA to its esteemed Board of Directors.

  February 21, 2024

   · 

  2 min read
• Pharm Country

  Predictive Oncology to Participate in Upcoming Investor Conferences

  Predictive Oncology Inc. (NASDAQ: POAI), a leader in AI-driven drug discovery and biologics, today announced that Raymond F. Vennare, Chief Executive Officer, will participate in three upcoming investor conferences.

  February 21, 2024

   · 

  2 min read
• Discover this new generic drug in the PERINDOPRIL range

  Pharmascience Canada is proud to announce the launch of pms-PERINDOPRIL-AMLODIPINE, a drug indicated for the treatment of mild to moderate essential hypertension in adults aged 18 to 65 for whom combination therapy is appropriate.

  February 21, 2024

   · 

  1 min read
• Business

  Kewaunee Scientific to Report Results for Third Quarter Fiscal Year 2024

  Kewaunee Scientific Corporation (NASDAQ: KEQU) today announced that the Company plans to release its third quarter fiscal year 2024 financial results on Wednesday, March 6, 2024 after the close of trading.

  February 21, 2024

   · 

  3 min read
• Business

  CareDx to Report Fourth Quarter and Full Year 2023 Financial Results

  CareDx, Inc. announced it will report financial results for the fourth quarter and full year 2023 after market close on Wednesday, February 28, 2024.

  February 21, 2024

   · 

  1 min read